News

The double-blind and placebo-controlled clinical study involving 40 healthy volunteers demonstrates the safety of topically applying FS2 cream at the maximum feasible dose with no adverse effects. The

The Company is issuing this press release to provide further heightened awareness of this recall and to provide instructions to consumers, pharmacists, and wholesalers in possession of the

Synacthen Depot is a depot formulation of Synacthen (tetracosactide), a synthetic 24 amino acid melanocortin receptor agonist. It is approved and marketed outside the US for several autoimmune

ND0612L is a low-dose continuous subcutaneously administered levodopa/carbidopa liquid formulation.  Parkinson’s disease is a progressive neurodegenerative illness characterized by reduced dopamine levels in the brain. The multicenter, double-blind, placebo-controlled

Utilizing Ironshore’s proprietary delayed-release and extended-release technology, DELEXIS, HLD100 is intended for nighttime dosing and is designed to control ADHD symptoms and improve functioning immediately upon awakening and

The joint venture, named iPharma, will develop innovative clinical and pre-clinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets. Under the terms

The trial  was a multicenter, randomized, double-blind, multiple-dose, placebo-controlled study evaluating the efficacy and safety of three dosing regimens of Buprenorphine Sublingual Spray (0.5 mg three times daily

The Company's SFX-01, a synthetic and stabilised version of sulforaphane, is currently in a Phase II trial, SAS (SFX-01 after Subarachnoid Haemorrhage), in the UK. The orphan drug

Novartis claims that the Expand study is the largest study ever undertaken in SPMS. More than 1,600 people with SPMS from 31 countries participated in the study. They